Objective:To explore risk factors of mucormycosis in COVID-19 recovered patients.Methods:A total of 101 patients,who were diagnosed with mucormycosis after recovery from COVID-19 and admitted to the Indira Gandhi Inst...Objective:To explore risk factors of mucormycosis in COVID-19 recovered patients.Methods:A total of 101 patients,who were diagnosed with mucormycosis after recovery from COVID-19 and admitted to the Indira Gandhi Institute of Medical Sciences,Patna,a tertiary care hospital in India,were included in the study.The presenting clinical features and associated risk factors were assessed and analyzed subsequently.Results:Of 101,68(67.3%)were males,and 33(32.7%)were females.A total of 89(88.1%)patients were between 46 and 65 years old.The most common subtypes were rhino-ocular(61.4%),followed by paranasal sinuses(16.8%),rhino-ocular cerebral(16.8%),ocular(3.0%),and pulmonary(2.0%).Diabetes mellitus was present in 71% of cases of mucormycosis as co-morbidities.A total of 76.2% of patients were given systemic corticosteroids in oral or intravenous form during COVID-19 treatment.Severe COVID-19 was present in 45.5% of patients with mucormycosis,while the moderate infection was present in 35.6% of mucormycosis.Most patients had gap between the onset of mucormycosis and COVID-19<15 d.Conclusions:A lethal confluence of uncontrolled diabetes mellitus,corticosteroid usage,and COVID-19 could cause a dramatic rise in mucormycosis.So,clinicians must be aware of these risk factors in patients suffering as well as recovering from COVID-19 to prevent mucormycosis.展开更多
文摘Objective:To explore risk factors of mucormycosis in COVID-19 recovered patients.Methods:A total of 101 patients,who were diagnosed with mucormycosis after recovery from COVID-19 and admitted to the Indira Gandhi Institute of Medical Sciences,Patna,a tertiary care hospital in India,were included in the study.The presenting clinical features and associated risk factors were assessed and analyzed subsequently.Results:Of 101,68(67.3%)were males,and 33(32.7%)were females.A total of 89(88.1%)patients were between 46 and 65 years old.The most common subtypes were rhino-ocular(61.4%),followed by paranasal sinuses(16.8%),rhino-ocular cerebral(16.8%),ocular(3.0%),and pulmonary(2.0%).Diabetes mellitus was present in 71% of cases of mucormycosis as co-morbidities.A total of 76.2% of patients were given systemic corticosteroids in oral or intravenous form during COVID-19 treatment.Severe COVID-19 was present in 45.5% of patients with mucormycosis,while the moderate infection was present in 35.6% of mucormycosis.Most patients had gap between the onset of mucormycosis and COVID-19<15 d.Conclusions:A lethal confluence of uncontrolled diabetes mellitus,corticosteroid usage,and COVID-19 could cause a dramatic rise in mucormycosis.So,clinicians must be aware of these risk factors in patients suffering as well as recovering from COVID-19 to prevent mucormycosis.
